Evaluation of oral administration of PRIM-DJ2727 capsule containing microbiota suspension in patients with severe alcoholic hepatitis: An Open-Label Study
严重酒精性肝炎患者口服含有微生物悬浮液的 PRIM-DJ2727 胶囊的评价:一项开放标签研究
基本信息
- 批准号:10686094
- 负责人:
- 金额:$ 23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-18 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adrenal Cortex HormonesAdverse effectsAdverse eventAlcoholic HepatitisAlcoholic Liver DiseasesAlcoholsBiochemicalBiological AssayBlindedCessation of lifeCirrhosisClinicalClinical TrialsClostridium difficileComplementControlled Clinical TrialsDataDeath CertificatesDiagnosisDiseaseDown-RegulationEffectivenessEligibility DeterminationEncephalopathiesEndotoxinsEthanolEvaluationFreeze DryingFundingFutureGastroenterologyGastrointestinal DiseasesGastrointestinal MotilityHeavy DrinkingHepatologyIcterusImmune responseIncidenceInstitutionIntakeIntestinal permeabilityLiverLiver CirrhosisLiver FailureLiver diseasesMaddrey scoreMedicalMedicineMicrobeModelingMonitorOralOral AdministrationOrganOutcomeParticipantPatient-Focused OutcomesPatientsPilot ProjectsPublic HealthRandomizedRandomized Controlled Clinical TrialsRecurrenceRegimenReportingResearch PersonnelRoleSafetySampling StudiesSteroid therapySteroidsSurvival RateSuspensionsSyndromeTestingTherapeuticTight JunctionsTimeToxic effectTubeUnited Statesantimicrobial peptidecapsulechronic alcohol ingestioncollegecostdesigndysbiosisefficacy evaluationend stage liver diseasefecal microbiomefecal transplantationfollow-upgenome sequencinggut dysbiosisgut microbiomegut microbiotagut-liver axisimprovedindexingliver functionliver transplantationmicrobialmicrobiomemicrobiotamortalityopen labelprognosticrecruitresponsesafety assessmentside effectstandard carestool sampletissue injurytooltreatment responsewhole genome
项目摘要
Alcoholic hepatitis (AH) is a major public health problem in the United States, in which 30-50% die within the
first 28 days. For the past few decades, steroid therapy has been the standard treatment in managing patients
with severe AH, however, it hasn’t significantly improved survival rates among these patients. Moreover,
shortage of organs and cost for liver transplantation are major barriers for liver transplantation in patients with
AH. There is growing evidence suggesting the role of the gut-liver axis in alcohol-induced tissue injury and liver
failure among heavy alcohol drinkers. The gut microbial community of patients with advanced alcoholic liver
diseases is known to be dysbiotic. Therefore, microbiome-directed therapy that can complement microbial
deficiencies in patients with AH may reduce complications of the diseases. Furthermore, over the last few years,
multiple studies have shown that fecal microbiome transplant (FMT) is a safe and more effective approach in
treatment of liver cirrhosis and recurrent encephalopathy. A recent study by Indian investigators showed that
modulation of intestinal microbiota has shown to improve survival in patients with severe AH. However, the
study faced some limitations including: limited longitudinal assessment of the prognostic scores for alcoholic
hepatitis, use of nasoduodenal tube to deliver fecal microbiome, and lack of detail in profiling of intestinal
microbiome. In this proposed clinical trial, we hypothesize that FMT in patients with severe AH will be safe and
will result in improvement of intestinal microbiome diversity which might contribute to improvement of
biochemical parameters, prognostic scores, and clinical outcome of the patients. To test this hypothesis, we
propose recruiting 12 patients with severe AH to participate in a single center trial using the Simon’s two-stage,
minimax design in which microbiome suspension containing capsules, called PRIM-DJ2727 will be
administered. The aims of this pilot study are as follows: 1) To explore the impact of FMT in improving the clinical
outcome of 12 patients with severe AH. Eligible patients will receive 10 does of PRIM-DJ2727 (30 grams/day)
for a week followed by once weekly for 3 weeks. We plan to assess FMT-response rate based on Lille score and
changes in biochemical parameters, prognostic scores, and overall survival. 2) To characterize gut microbiome
diversity associated with severe alcoholic hepatitis patients at several time points during and post-FMT; this will
be done through analyzing stool samples using whole genome sequencing at weeks (1 & 4) and at months (3 &
6). Despite no evidence to support severe adverse effects for FMT administration in patients with liver diseases,
we aimed to monitor the study participants for treatment safety. This proposed study may have a major impact
on the field of hepatology. It will shed the light on the potential use of FMT as a safe, effective and affordable tool
in managing patients with severe AH. Results from this pilot study may prompt future conduct of large scale
randomized controlled clinical trials for FMT use in severe AH. This may later assist in transforming medical
management in the gastroenterology field by opening doors for use of FMT in multiple gastrointestinal disorders.
酒精性肝炎(AH)是美国的一个主要公共卫生问题,其中30-50%的人在24小时内死亡。
前28天在过去的几十年里,类固醇治疗一直是管理患者的标准治疗方法
然而,对于严重的AH,它并没有显著提高这些患者的生存率。此外,委员会认为,
器官短缺和肝移植费用是肝移植患者的主要障碍,
啊越来越多的证据表明肠-肝轴在酒精诱导的组织损伤和肝脏损伤中的作用。
酗酒者的失败。晚期酒精性肝病患者肠道菌群的研究
已知疾病是生态失调的。因此,可以补充微生物的微生物组导向疗法
在AH患者中的缺乏可以减少疾病的并发症。此外,在过去的几年里,
多项研究表明,粪便微生物组移植(FMT)是一种安全且更有效的方法,
治疗肝硬化和复发性脑病。印度调查人员最近的一项研究显示,
肠道微生物群的调节已经显示出改善患有严重AH的患者的存活率。但
这项研究面临一些局限性,包括:对酒精中毒患者预后评分的纵向评估有限,
肝炎,使用鼻十二指肠管输送粪便微生物组,以及缺乏肠道微生物分析的细节
微生物组在这项拟议的临床试验中,我们假设FMT在重度AH患者中是安全的,
将导致肠道微生物组多样性的改善,这可能有助于改善
患者的生化参数、预后评分和临床结果。为了验证这个假设,我们
建议招募12名重度AH患者参加单中心试验,采用Simon的两阶段,
最小最大设计,其中将使用含有微生物群悬浮液的胶囊,称为PRIM-DJ 2727,
管理。本研究的目的如下:1)探讨FMT在改善临床症状方面的作用,
12例重度AH患者的结局。合格患者将接受10剂PRIM-DJ 2727(30克/天)
持续一周,然后每周一次持续3周。我们计划根据里尔评分评估FMT应答率,
生化参数、预后评分和总生存率的变化。2)表征肠道微生物组
在FMT期间和FMT后的几个时间点与重度酒精性肝炎患者相关的多样性;这将
通过使用全基因组测序在第1周(1和4周)和第3个月(3和
6)。尽管没有证据支持FMT给药对肝病患者的严重不良反应,
我们的目的是监测研究参与者的治疗安全性。这项拟议中的研究可能会产生重大影响
在肝病学领域。它将揭示裂变材料条约作为一种安全、有效和负担得起的工具的潜在用途
严重AH患者的治疗。这项试点研究的结果可能会促进未来大规模的
FMT用于重度AH的随机对照临床试验。这可能有助于医疗转型
通过在多种胃肠道疾病中打开使用FMT的大门,在胃肠病学领域进行管理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Prasun Kumar Jalal其他文献
Prasun Kumar Jalal的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Prasun Kumar Jalal', 18)}}的其他基金
Evaluation of oral administration of PRIM-DJ2727 capsule containing microbiota suspension in patients with severe alcoholic hepatitis: An Open-Label Study
严重酒精性肝炎患者口服含有微生物悬浮液的 PRIM-DJ2727 胶囊的评价:一项开放标签研究
- 批准号:
10527603 - 财政年份:2022
- 资助金额:
$ 23万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 23万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 23万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 23万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 23万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 23万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 23万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 23万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 23万 - 项目类别:
Studentship